| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/05/2005 | EP1492772A1 Farnesyl protein transferase inhibitors as antitumor agents |
| 01/05/2005 | EP1492771A1 Quinoline and isoquinoline derivatives, method for the production thereof and use thereof as anti-inflammatory agents |
| 01/05/2005 | EP1492769A2 Novel process |
| 01/05/2005 | EP1492767A1 Certain 1-(d-cyclopropylglycinyl)-4-(piperidin-4-yl)piperazine compounds as inhibitors of the serine protease factor xa |
| 01/05/2005 | EP1492766A1 Improved cc-1065 analog synthesis |
| 01/05/2005 | EP1492765A2 Novel gamma secretase inhibitors |
| 01/05/2005 | EP1492763A1 Carboxamidine derivatives and their use in the treatment of vascular diseases |
| 01/05/2005 | EP1492761A2 Amino acids with affinity for the alpha-2-delta-protein |
| 01/05/2005 | EP1492757A1 (2-((2-alkoxy)-phenyl)-cyclopent-1-enyl) aromatic carbo- and heterocyclic carboxylic acid and derivatives |
| 01/05/2005 | EP1492756A1 Novel thyroid receptor ligands |
| 01/05/2005 | EP1492595A1 Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist |
| 01/05/2005 | EP1492571A2 Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands |
| 01/05/2005 | EP1492569A1 Aqueous dispersible steryl ester compositions |
| 01/05/2005 | EP1492568A1 Cancer treatment method comprising administration of an erb-family inhibitor and a raf and/or ras inhibitor |
| 01/05/2005 | EP1492567A1 Formulations and methods of using nitric oxide mimetics in cancer treatment |
| 01/05/2005 | EP1492563A2 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
| 01/05/2005 | EP1492560A2 Use of interleukin-19 to treat cervical cancer |
| 01/05/2005 | EP1492555A2 Compositions and methods for modulation of effects on phagocyte and lymphoid cell population |
| 01/05/2005 | EP1492552A2 Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1) |
| 01/05/2005 | EP1492551A2 Ophthalmic, pharmaceutical and other healthcare preparations with naturally occuring plant compounds, extracts and derivatives |
| 01/05/2005 | EP1492549A1 Compositions and methods for augmenting kidney function |
| 01/05/2005 | EP1492546A1 Use of pyrimidine nucleotides for the treatment of affections of the peripheral nervous system |
| 01/05/2005 | EP1492545A1 Agents for treating i flaviviridae /i infections |
| 01/05/2005 | EP1492544A1 Pharmaceutical compositions containing water-soluble prodrugs of propofol and methods of administering same |
| 01/05/2005 | EP1492543A1 Drugs for the arthritis treatment |
| 01/05/2005 | EP1492542A1 Hormone replacement therapy |
| 01/05/2005 | EP1492541A1 Pharmaceutical compositions comprising a 11-beta hydroxysteroid dehydrogenase inhibitor and a diuretic agent |
| 01/05/2005 | EP1492540A1 The use of devazepide as analgesic agent |
| 01/05/2005 | EP1492539A1 Statin therapy for enhancing cognitive maintenance |
| 01/05/2005 | EP1492538A1 Meloxicam suppositories containing e.g. polyethylenglycol |
| 01/05/2005 | EP1492536A1 4-(n-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors |
| 01/05/2005 | EP1492534A1 Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors |
| 01/05/2005 | EP1492533A1 N-substituted pyridinone and pyrimidinone derivatives for use as lp-pla2 inhibitors in the treatment of artherosclerosis |
| 01/05/2005 | EP1492532A1 Combinations of epinastine, belladonna and pseudoephedrine as new pharmaceutical formulations |
| 01/05/2005 | EP1492531A2 Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillin |
| 01/05/2005 | EP1492530A1 Thiazol-2-yl-imine compounds as pde-7 inhibitors |
| 01/05/2005 | EP1492529A1 Oral administration of epothilones |
| 01/05/2005 | EP1492528A1 Antidiabetic agents |
| 01/05/2005 | EP1492527A2 Process for preparing a finely self-emulsifiable pharmaceutical composition |
| 01/05/2005 | EP1492526A2 Improved prodrugs of cc-1065 analogs |
| 01/05/2005 | EP1492525A2 Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphosphate concentration dependent on intracellular signal cascades |
| 01/05/2005 | EP1492524A1 Vitamin combination for providing protection during the chemotherapy and/or radiotherapy of malignant tumours |
| 01/05/2005 | EP1492523A2 Method for identification of tumor targeting enzymes |
| 01/05/2005 | EP1492522A1 Ansamycin formulations and methods for producing and using same |
| 01/05/2005 | EP1492521A1 Combined use of l-carnitine, acetyl l-carnitine and propionyl l-carnitine for the treatment of oligoasthenoteratospermia |
| 01/05/2005 | EP1492520A1 Pharmaceutical compositions |
| 01/05/2005 | EP1492519A1 Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators |
| 01/05/2005 | EP1492518A2 Tuberculosis treatment using pleuromutilin derivatives |
| 01/05/2005 | EP1492517A2 Hot melt tts for administering rotigotine |
| 01/05/2005 | EP1492516A2 Use of mob-5 in pain |
| 01/05/2005 | EP1492515A1 Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male |
| 01/05/2005 | EP1492513A1 Hfa-suspension formulations containing an anticholinergic |
| 01/05/2005 | EP1492511A2 Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
| 01/05/2005 | EP1492510A1 Low dose liquid entecavir formulations and use |
| 01/05/2005 | EP1492509A1 Dosage form providing time-varying patterns of drug delivery |
| 01/05/2005 | EP1492508A1 Controlled release dosage forms |
| 01/05/2005 | EP1492507A2 Clarithromycin formulations having improved bioavailability |
| 01/05/2005 | EP1492506A2 Matrix for sustained, invariant and independent release of active compounds |
| 01/05/2005 | EP1492505A2 Pharmaceutical preparation containing oxycodone and naloxone |
| 01/05/2005 | EP1492504A2 Taste masked compositions of erythromycin a and derivatives thereof |
| 01/05/2005 | EP1492503A1 Stabilized natural cannabinoid formulation |
| 01/05/2005 | EP1492502A1 Novel polymorphs and pseudopolymorphs of risedronate sodium |
| 01/05/2005 | EP1492501A1 Methods of using lamellar bodies for therapeutic purposes |
| 01/05/2005 | EP1492500A1 Formoterol and ciclesonide aerosol formulations |
| 01/05/2005 | EP1492499A1 Formoterol and mometasone aerosol formulations |
| 01/05/2005 | EP1492498A2 Hfa-suspension formulation of an anhydrate |
| 01/05/2005 | EP1492487A2 Mitotic kinesin inhibitors |
| 01/05/2005 | EP1492486A2 Urea compositions |
| 01/05/2005 | EP1492419A1 Use of creatine pyruvate for increasing stamina during highly intensive intermittent physical exertion |
| 01/05/2005 | EP1492415A2 Method of improving absorption of vitamin e by a pet animal |
| 01/05/2005 | EP1492414A2 Method and dietary composition for improving fat digestibility |
| 01/05/2005 | EP1492413A2 Method and dietary composition for improving lipid digestibility |
| 01/05/2005 | EP1442038A4 Crystalline forms of carbapenem antibiotics and methods of preparation |
| 01/05/2005 | EP1429791A4 Method and topical formulation for treating skin conditions associated with aging |
| 01/05/2005 | EP1420643A4 Enhancement of transfection of dna into the liver |
| 01/05/2005 | EP1411909B1 Pharmaceutical composition comprising (-)-secoisolariciresinol |
| 01/05/2005 | EP1397138B1 ACTIVE INGREDIENT COMBINATION (e.g. galanthamine or desoxypeganine with acamprosate or Memantine) FOR TREATING A DEPENDENCE ON ADDICTIVE SUBSTANCES OR NARCOTICS |
| 01/05/2005 | EP1318792B1 Sustained release composition containing clarithromycin |
| 01/05/2005 | EP1282414B1 Felbamate derived compounds for treating neuropathic pain |
| 01/05/2005 | EP1274687B1 1,2,3,4- tetrahydroisoquinoline derivatives |
| 01/05/2005 | EP1261358B1 Use of a composition comprising morinda citrifolia for the treatment of tinnitus |
| 01/05/2005 | EP1248630B9 Use of a dermatological composition containing oligosaccharides for the treatment of skin diseases |
| 01/05/2005 | EP1244440B1 Agonists specific for the peripheral cannabinoid receptor |
| 01/05/2005 | EP1239837B1 Direct compression polymer tablet core |
| 01/05/2005 | EP1227814B1 Hormonal composition based on nomegestrol acetate and an oestrogen and use thereof |
| 01/05/2005 | EP1226126B1 Pyrimidine derivatives |
| 01/05/2005 | EP1200580B1 MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
| 01/05/2005 | EP1178801B1 Combination of nicotinic acid or nicotinamide with riboflavin for the treatment of pruritus, itching and inflammation disorders |
| 01/05/2005 | EP1171134A4 Controlled release of sildenafil delivered by sublingual or buccal administration |
| 01/05/2005 | EP1150648A4 Use of water-soluble/dispersible reactive derivatives of polyimido compounds for modifying proteinaceous substrates |
| 01/05/2005 | EP1133300B1 Desmethylolanzapine compositions and methods |
| 01/05/2005 | EP1109537B1 Immediate release oral formulation comprising peptide thrombin inhibitors and a combination of microcrystalline cellulose and sodium starch glycollate |
| 01/05/2005 | EP1073413B1 Methods and compositions for stabilizing acetylcholine compositions |
| 01/05/2005 | EP1032371B1 Polyethylene glycol matrix pellets for greasy, oily or sticky drug substances |
| 01/05/2005 | EP1031351B1 Leishmaniasis remedy containing glucopyranose derivative as the active ingredient |
| 01/05/2005 | EP1027349B1 Tetrahydrofuran phosphate- and hydroxy esters, as prodrugs for the corresponding antifungal agent |
| 01/05/2005 | EP1027051B1 Antithrombotic agents |
| 01/05/2005 | EP1015449B1 (hetero)aryl-sulfonamide derivatives, their preparation and their use as factor xa inhibitors |
| 01/05/2005 | EP1006110B8 Derivatives of acyl-piperazinil-pyrimidins, preparation thereof and application as medicaments |
| 01/05/2005 | EP1003488B1 Method for preparing vesicular nanocapsules |